The biological effects of isoform-specific PI3-kinase inhibition

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 1, 2010, Pages 41-49

  Ihle, Nathan T ^a   Powis, Garth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; PI3K; PI3K inhibitor; PI3K isoform; Therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AZD 6482; CAL 101; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; XL 147; XL 765;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; DRUG INHIBITION; DRUG STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; REVIEW; THROMBOSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ENZYME INHIBITORS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 73849094834     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 4(12):988-1004.
2. Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 253(1):239-254.
3. Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem (1998) 67:481-507.
4. Backer JM: The regulation and function of class III PI3Ks: Novel roles for Vps34. Biochem J (2008) 410(1):1-17.
5. Kuruvilla FG, Schreiber SL: The PIK-related kinases intercept conventional signaling pathways. Chem Biol (1999) 6(5):R129-R136.
6. Inukai K, Funaki M, Ogihara T, Katagiri H, Kanda A, Anai M, Fukushima Y, Hosaka T, Suzuki M, Shin BC, Takata K et al: p85α gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-kinase), p50α, p55α, and p85α, with different PI 3-kinase activity elevating responses to insulin. J Biol Chem (1997) 272(12):7873-7882.
7. Toker A: Phosphoinositides and signal transduction. Cell Mol Life Sci (2002) 59(5):761-779.
8. Dong LQ, Liu F: PDK2: The missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab (2005) 289(2):E187-E196.
9. Manning BD, Cantley LC: Akt/PKB signaling: Navigating downstream. Cell (2007) 129(7):1261-1274.
10. Huang J, Manning BD: The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J (2008) 412(2):179-190.
11. Meier TI, Cook JA, Thomas JE, Radding JA, Horn C, Lingaraj T, Smith MC: Cloning, expression, purification, and characterization of the human class Ia phosphoinositide 3-kinase isoforms. Protein Expr Purif (2004) 35(2):218-224.
12. Denley A, Kang S, Karst U, Vogt PK: Oncogenic signaling of class I PI3K isoforms. Oncogene (2008) 27(18):2561-2574.
13. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL: Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J Biol Chem (1999) 274(16):10963-10968.
14. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ et al: Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature (2008) 453(7195): 662-666.
15. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B: Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 441(7091):366-370.
16. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD et al: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB ?. J Clin Invest (2003) 112(2):197-208.
17. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T et al: A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell (2006) 125(4):733-747.
18. Lu Z, Jiang YP, Wang W, Xu XH, Mathias RT, Entcheva E, Ballou LM, Cohen IS, Lin RZ: Loss of cardiac phosphoinositide 3-kinase p110α results in contractile dysfunction. Circulation (2009) 120(4):318-325.
19. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah J et al: Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 110(6):737-749.
20. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S: Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA (2003) 100(21):12355-12360.
21. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J: Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice. Cell (2007) 129(5):957-968.
22. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK et al: High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 304(5670):554. (Pubitemid 38541907)
23. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM: The oncogenic properties of mutant p110α and p110α phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA (2005) 102(51):18443-18448.
24. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7(6):561-573.
25. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF et al: Akt-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 16(1):21-32.
26. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, Frangioni JV, Cantley LC: Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA (2008) 105(28):9739-9744.
27. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ: Essential roles of PI(3)K-p110α in cell growth, metabolism and tumorigenesis. Nature (2008) 454(7205):776-779.
28. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA et al: PI 3-kinase p110α: A new target for antithrombotic therapy. Nat Med (2005) 11(5):507-514.
29. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W et al: Phosphoinositide 3-kinase p110α activity: Key role in metabolism and mammary gland cancer but not development. Sci Signal (2008) 1(36):ra3.
30. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition. Biochem J (2008) 415(1):97-110.
31. Christoforidis S, Miaczynska M, Ashman K, Wilm M, Zhao L, Yip SC, Waterfield MD, Backer JM, Zerial M: Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat Cell Biol (1999) 1(4):249-252.
32. Hirsch E, Braccini L, Ciraolo E, Morello F, Perino A: Twice upon a time: PI3K's secret double life exposed. Trends Biochem Sci (2009) 34(5):244-248.
33. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Selpekar A, Waterfield MD, Smith AJ et al: Impaired B and T cell antigen receptor signaling in p110α PI 3-kinase mutant mice. Science (2002) 297(5583):1031-1034.
34. Kok K, Nock GE, Verrall EA, Mitchell MP, Hommes DW, Peppelenbosch MP, Vanhaesebroeck B: Regulation of p110α PI3-kinase gene expression. PLoS One (2009) 4(4):e5145.
35. Okkenhaug K, Patton DT, Bilancio A, Garçon F, Rowan WC, Vanhaesebroeck B: The p110α isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol (2006) 177(8):5122-5128.
36. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B: Key role of the p110α isoform of PI3K in B-cell antigen and IL-4 receptor signaling: Comparative analysis of genetic and pharmacologic interference with p110α function in B cells. Blood (2006) 107(2):642-650.
37. Rommel C, Camps M, Ji H: PI3K δ and PI3K γ: Partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol (2007) 7(3):191-201.
38. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddlings J, Peskett E, Fox R et al: Essential role for the p110α phosphoinositide 3-kinase in the allergic response. Nature (2004) 431(7011):1007-1011.
39. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, Hunault-Berger M et al: Essential role for the p110α isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 106(3):1063-1066.
40. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J, Jones GE, Vanhaesebroeck B: Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110α. Cancer Res (2003) 63(7):1667-1675.
41. Geng L, Tan J, Himmelfarb E, Schueneman A, Niermann K, Brousal J, Fu A, Cuneo K, Kesicki EA, Treiberg J, Hayflick JS et al: A specific antagonist of the p110α catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiationinduced tumor vascular destruction. Cancer Res (2004) 64(14):4893-4899.
42. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, Joza N et al: Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science (2000) 287(5455):1040-1046.
43. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann MP: Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity (2002) 16(3):441-451.
44. Madeddu P, Kraenkel N, Barcelos LS, Siragusa M, Campagnolo P, Oikawa A, Caporali A, Herman A, Azzolino O, Barberis L, Perino A et al: Phosphoinositide 3-kinase gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterio Thromb Vasc Biol (2008) 28(1):68-76.
45. Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K, Kauffenstein G, Rewcastle GW et al: Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin ? IIb ? 3 adhesive function in platelets. J Biol Chem (2007) 282(39):28648-28658.
46. Hickey FB, Cotter TG: Bcr-abl regulates phosphatidylinositol 3-kinase-p110α transcription and activation and is required for proliferation and drug resistance. J Biol Chem (2006) 281(5):2441-2450.
47. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin SD, Silengo L et al: PI3K? modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell (2004) 118(3):375-387.
48. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl- 4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 269(7):5241-5248.
49. Matter WF, Brown RF, Vlahos CJ: The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun (1992) 186(2):624-631.
50. Nakanishi S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T, Yamada K, Yoshida M, Kase H, Matsuda Y, Hashimoto Y et al: Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem (1992) 267(4):2157-2163.
51. Arcaro A, Wymann MP: Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J (1993) 296(Pt 2):297-301.
52. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J (2007) 404(1):15-21.
53. Ihle NT, Powis G: Take your PIK: Phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther (2009) 8(1):1-9.
54. Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD: Inhibition of phosphoinositide 3-kinaseγ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J (2006) 20(3):455-465.
55. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, Khwaja A: A selective inhibitor of the p110α isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene (2006) 25(50):6648-6659.
56. Marone R, Cmiljanovic V, Giese B, Wymann MP: Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim Biophys Acta (2008) 1784(1):159-185.
57. Friedman L: GDC-0941, a potent, selective, orally bioavailable inhibitor of class I PI3K. AACR Annual Meeting (2008) 99:Abs LB- 110.
58. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G: The phosphatidylinositol-3- kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther (2005) 4(9):1349-1357.
59. Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K et al: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 12(7):852-855.
60. Amzel LM, Huang CH, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B: Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 8(9):665-669.
61. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K et al: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA (2008) 105(8):3041-3046.
62. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR et al: Effective use of PI3K and MEK inhibitors to treat mutant KRas G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14(12):1351-1356.
63. Parsons R: Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol (2004) 15(2):171-176.
64. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA: A dual phosphoinositide-3-kinaseγ /mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 67(17):7960-7965.
65. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 66(3):1500-1508.
66. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D et al: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 7(7): 1851-1863.
67. Foster PG: Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2007):Abs C199.
68. Laird DA: XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2007):Abs B250.
69. Claussade C, Rewcastle GW, Kendell JD, Denny WA, Cho K, Gronning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR: Evidence for functional redundancy of class IA PI3K isoforms in insulin signaling. Biochem J (2007) 404(3):449-458.
70. Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G: Peroxisome proliferator-activated receptor ? agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther (2009) 8(1):94-100.
71. Shipiro GI, Edelman G, Calvo E, Aggerwal SK, Laird AD: Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavaliable PI3K inhibitor. AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics (2007):Abs C205.